Extremely promising clinical trial results for the high-sensitivity Point-of-Care (POC) cardiac troponin I test of our partner SpinChip Diagnostics
SpinChip Diagnostics, in which bioMérieux has held an approximate 20% stake since March 2024, has just published results showing the very good performance of its high-sensitivity Point-of-Care (POC) cardiac troponin I (hs-cTnI) assay. This innovative assay, the first of its kind, could significantly improve the diagnosis of acute myocardial infarction.
Published in the prestigious Journal of the American College of Cardiology (1) by Drs Luca Koechlin and Jasper Boeddinghaus, the findings of the APACE (Advantageous Predictors of Acute Coronary Syndromes Evaluation) study, evaluated the clinical and analytical performance of SpinChip’s innovative assay. Conducted in collaboration with Basel University Hospital in Switzerland and Akershus University Hospital in Norway, the study demonstrates the assay’s very high diagnostic capabilities.
Professor Christian Mueller, Co-founder and Director of the Cardiovascular Research Institute in Basel, Switzerland, who leads the APACE study, praised the assay, stating, “The novel Point-of-Care SpinChip high-sensitivity cardiac Troponin I test demonstrated comparable diagnostic performance with the best-validated central laboratory assays. The results are impressive and very good news for both patients and physicians.”
The study highlights the potential of this technology to expedite acute myocardial infarction diagnosis and treatment in emergency departments, potentially reducing overcrowding and healthcare costs. Furthermore, the assay’s high agreement across various sample types—whole blood, fresh/frozen plasma, and capillary finger prick— supports its possible use in various clinical settings, including prehospital care, general practice, and remote locations. This expands the potential applications of the hs-cTnI-SPINCHIP assay, making hs troponin testing more accessible. In an editorial in the same issue of JACC, Dr Aldo Clerico (Cardiology Division of Pisa, Italy) writes "The comparable diagnostic performance of the hs-cTnI-SPINCHIP to central laboratory assays suggests that POCT could become a valuable tool in the early triage and management of patients with suspected MI" and "the hs-cTnI-SPINCHIP POCT assay offers a promising advancement in the rapid and accurate diagnosis of MI, with significant potential to improve patient outcomes and streamline workflow in the ED."(2)
SpinChip is developing and producing a game-changing all-in-one POC platform for near patient testing based on immunoassay technology. This platform delivers precise diagnostic results within minutes from just a droplet of blood. The cardiac troponin I assay is the first test available on this platform.
SpinChip all-in-one POC platform
*References
1. J Am Coll Cardiol 2024;84:726 – 740
2. J Am Coll Cardiol 2024;84:741 – 743
